Amylyx Pharmaceuticals, Inc. Increase (Decrease) in Accrued Interest Receivable, Net
Amylyx Pharmaceuticals, Inc. (AMLX) reported Increase (Decrease) in Accrued Interest Receivable, Net of -$24.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-03.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet · last filed 2026-03-03
- Amylyx Pharmaceuticals, Inc. increase (decrease) in accrued interest receivable, net for the quarter ending 2025-12-31 was -$6.00K.
- Amylyx Pharmaceuticals, Inc. increase (decrease) in accrued interest receivable, net for the quarter ending 2025-09-30 was $55.00K, a 53.39% decline year-over-year.
- Amylyx Pharmaceuticals, Inc. increase (decrease) in accrued interest receivable, net for the quarter ending 2025-06-30 was -$7.00K.
- Amylyx Pharmaceuticals, Inc. increase (decrease) in accrued interest receivable, net for the quarter ending 2025-03-31 was -$66.00K.
- Amylyx Pharmaceuticals, Inc. increase (decrease) in accrued interest receivable, net for fiscal 2025 was -$24.00K.
- Amylyx Pharmaceuticals, Inc. increase (decrease) in accrued interest receivable, net for fiscal 2024 was -$359.00K.
- Amylyx Pharmaceuticals, Inc. increase (decrease) in accrued interest receivable, net for fiscal 2023 was -$23.00K.
- Amylyx Pharmaceuticals, Inc. increase (decrease) in accrued interest receivable, net for fiscal 2022 was -$487.00K, a 438.19% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accrued Interest Receivable, Net 3 month | Increase (Decrease) in Accrued Interest Receivable, Net 6 month | Increase (Decrease) in Accrued Interest Receivable, Net 9 month | Increase (Decrease) in Accrued Interest Receivable, Net 12 month |
|---|---|---|---|---|
| 2025-12-31 | -$6.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $49.00K derived: sum of 2 quarters · filed 2026-03-03 | $42.00K derived: sum of 3 quarters · filed 2026-03-03 | -$24.00K 10-K · filed 2026-03-03 |
| 2025-09-30 | $55.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $48.00K derived: sum of 2 quarters · filed 2025-11-06 | -$18.00K 10-Q · filed 2025-11-06 | -$74.00K derived: sum of 4 quarters · filed 2026-03-03 |
| 2025-06-30 | -$7.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$73.00K 10-Q · filed 2025-08-07 | -$129.00K derived: sum of 3 quarters · filed 2026-03-03 | -$11.00K derived: sum of 4 quarters · filed 2026-03-03 |
| 2025-03-31 | -$66.00K 10-Q · filed 2025-05-08 | -$122.00K derived: sum of 2 quarters · filed 2026-03-03 | -$4.00K derived: sum of 3 quarters · filed 2026-03-03 | -$308.00K derived: sum of 4 quarters · filed 2026-03-03 |
| 2024-12-31 | -$56.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $62.00K derived: sum of 2 quarters · filed 2026-03-03 | -$242.00K derived: sum of 3 quarters · filed 2026-03-03 | -$359.00K 10-K · filed 2026-03-03 |
| 2024-09-30 | $118.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$186.00K derived: sum of 2 quarters · filed 2025-11-06 | -$303.00K 10-Q · filed 2025-11-06 | $44.00K derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | -$304.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$421.00K 10-Q · filed 2025-08-07 | -$74.00K derived: sum of 3 quarters · filed 2025-08-07 | -$800.00K derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | -$117.00K 10-Q · filed 2025-05-08 | $230.00K derived: sum of 2 quarters · filed 2025-05-08 | -$496.00K derived: sum of 3 quarters · filed 2025-05-08 | $113.00K derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $347.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | -$379.00K derived: sum of 2 quarters · filed 2024-11-07 | $230.00K derived: sum of 3 quarters · filed 2024-11-07 | -$23.00K 10-K · filed 2024-02-22 |
| 2023-09-30 | -$726.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$117.00K derived: sum of 2 quarters · filed 2024-11-07 | -$370.00K 10-Q · filed 2024-11-07 | -$918.00K derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $609.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $356.00K 10-Q · filed 2024-08-08 | -$192.00K derived: sum of 3 quarters · filed 2024-08-08 | -$144.00K derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$253.00K 10-Q · filed 2024-05-09 | -$801.00K derived: sum of 2 quarters · filed 2024-05-09 | -$753.00K derived: sum of 3 quarters · filed 2024-05-09 | -$741.00K derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | -$548.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | -$500.00K derived: sum of 2 quarters · filed 2024-02-22 | -$488.00K derived: sum of 3 quarters · filed 2024-02-22 | -$487.00K 10-K · filed 2024-02-22 |
| 2022-09-30 | $48.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $60.00K derived: sum of 2 quarters · filed 2023-11-09 | $61.00K 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $12.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $13.00K 10-Q · filed 2023-08-10 | ||
| 2022-03-31 | $1.00K 10-Q · filed 2023-05-11 | |||
| 2021-12-31 | $144.00K 10-K · filed 2024-02-22 | |||
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $2.00K 10-Q · filed 2022-08-11 | ||
| 2021-03-31 | $2.00K 10-Q · filed 2022-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |